APPENDIX A: SAMPLE OF HARRIS COUNTY EXPENDITURES FOR AT-ISSUE PRODUCTS $2013-2018^*$

Grand Total	\$27,531,371.68
Grand Total	Ψ21,0001,011,000

	ELI LILLY AND COMPANY				
At-Issue Drugs	Type of Product	Harris Cost			
TOTAL		\$11,912,189.50			
Basaglar	Analog (Long-Acting)	\$360,502.64			
2017		\$21,007.48			
2018		\$339,495.16			
Humalog	Analog (Rapid-Acting)	\$4,849,376.34			
2013		\$303,322.15			
2014		\$440,247.93			
2015		\$550,441.08			
2016		\$660,364.97			
2017		\$1,238,628.89			
2018		\$1,656,371.32			
Humulin	Human	\$1,543,186.63			
2013		\$174,123.37			
2014		\$198,524.78			
2015		\$194,258.90			
2016		\$252,211.75			
2017		\$355,511.18			
2018		\$368,556.65			
Trulicity	Type 2 Medication	\$5,159,123.89			
2014		\$1,922.15			
2015		\$133,281.05			
2016		\$487,987.73			
2017		\$1,843,972.03			
2018		\$2,691,960.93			

^{*} These charts reflect current available expenditure data; it does not present Harris County's total spend on drugs atissue for the entire relevant time period.

NOVO NORDISK				
At-Issue Drugs		Harris Cost		
TOTAL		\$8,967,429.34		
Levemir	Analog (Long-Acting)	\$1,539,038.29		
2013		\$154,726.22		
2014		\$277,977.85		
2015		\$378,555.06		
2016		\$381,859.09		
2017		\$59,282.04		
2018		\$286,638.03		
Novolin	Human	\$77,513.10		
2013		\$12,875.91		
2014		\$17,308.67		
2015		\$20,842.82		
2016		\$19,023.14		
2017		\$4,613.28		
2018		\$2,849.28		
Novolog	Analog (Rapid-Acting)	\$2,674,718.89		
2013		\$367,965.14		
2014		\$543,406.81		
2015		\$674,211.85		
2016		\$854,419.52		
2017		\$191,628.11		
2018		\$43,087.46		
Ozempic	Type 2 Medication	\$163,884.56		
2018		\$163,884.56		
Tresiba	Analog (Long-Acting)	\$1,056,794.18		
2016		\$117,749.33		
2017		\$143,106.87		
2018		\$795,937.98		
Victoza	Type 2 Medication	\$3,455,480.32		
2013		\$426,390.36		
2014		\$694,315.01		
2015		\$799,151.18		
2016		\$982,472.81		
2017		\$301,734.18		
2018		\$251,416.78		

SANOFI-AVENTIS				
At-Issue Drugs		Harris Cost		
TOTAL		\$6,651,752.84		
Apidra	Analog (Rapid-Acting)	\$537,691.29		
2013		\$60,575.29		
2014		\$105,570.85		
2015		\$148,698.70		
2016		\$153,630.34		
2017		\$44,789.28		
2018		\$24,426.83		
Lantus	Analog (Long-Acting)	\$5,254,721.30		
2013		\$724,796.93		
2014		\$1,100,704.39		
2015		\$1,092,002.94		
2016		\$1,082,001.90		
2017		\$964,726.09		
2018		\$290,489.05		
Soliqua	Type 2 Medication	\$46,526.35		
2017		\$16,556.14		
2018		\$29,970.21		
Toujeo	Analog (Long-Acting)	\$812,813.90		
2015		\$72,092.54		
2016		\$265,194.81		
2017		\$421,820.12		
2018		\$53,706.43		